Full Breakdown
Light-Powered LEAF Eye Drops Show Preclinical Success Against Dry Eye
5/16/2026, 11:58:06 PM
LEAF Eye Drops Generate Light-Driven NADPH to Treat Dry Eye
The research team at the National University of Singapore, led by Associate Professor David Leong Tai Wei, has engineered a nanosized photosynthetic construct named LEAF (Light-reaction Enriched thylAkoid NADPH-Foundry). Delivered as eye drops, LEAF harvests ambient light to produce nicotinamide adenine dinucleotide phosphate (NADPH) directly inside corneal cells. By supplying NADPH, the system interrupts the reactive-oxygen-species (ROS) feedback loop that underlies dry eye disease, restoring tissue integrity without relying on conventional anti-inflammatory drugs.
Scale of the Problem
Dry eye disease (keratoconjunctivitis sicca) affects over 1.5 billion people worldwide and imposes an estimated US$3.84 billion annual productivity loss in the United States alone.
Photosynthetic Engineered Particles
LEAF particles are derived from spinach thylakoid grana using a patented mild extraction method, retain the light-reaction membranes, and are trimmed of NADPH-consuming components. At roughly 400 nm in diameter, they generate about 20 percent more NADPH than unpackaged thylakoids when illuminated.
Preclinical Outcome
In preclinical studies, eye-drop administration at doses that do not affect colour perception reversed corneal damage to near-healthy levels within five days, outperforming the approved drug Restasis®. The findings were published online in Cell on 15 May 2026.
Official Perspectives
Associate Professor Leong noted that LEAF directly supplies NADPH to break the ROS-driven ‘death spiral’ in dry eye. Dr Xing emphasized the broader significance of introducing plant photosynthesis into mammalian tissue.
Remaining Uncertainties
The study provides only preclinical data; human safety, optimal dosing, and long-term effects remain unverified and await replication. The work illustrates that plant photosynthetic components can be repurposed for mammalian therapeutic applications.
Verbatim Quotes
> “This is an exciting finding as we have, for the first time, demonstrated that plant photosynthetic machinery can be transplanted into mammalian tissue to generate biologically useful molecules, powered entirely by the same light that enables our vision. We, too, can have limited photosynthetic abilities.” — Dr Xing Kuoran, First Author, NUS
> “Current treatments such as cyclosporine A (Restasis®) and lifitegrast (Xiidra®) target inflammation through specific molecular pathways, but their high costs and adverse side effects limit long-term use.” — NUS News, Communications
> “In preclinical studies, the technology, delivered as simple eye drops at doses so low that it does not interfere with colour perception, reversed corneal damage to near-healthy levels within five days, outperforming Restasis®.” — NUS News, Communications
> “LEAF, when in the cells, then produces photosynthetic NADPH upon exposure to ambient light sources, and the NADPH produced tackles dry eye disease via two pathways – inside and outside the cell.” — NUS News, Communications
> “The study was published online in the scientific journal Cell on 15 May 2026.” — NUS News, Communications
